An Open-label, Phase 1b Study of Intravenously Administered Pegylated Liposomal Mitomycin C Lipid-based Prodrug (PROMITIL) in Combination With External Beam Radiotherapy in Patients With Advanced Cancer Requiring Palliative Radiotherapy
Latest Information Update: 03 Aug 2022
At a glance
- Drugs PL MLP (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LIPORAD-2018
- Sponsors Lipomedix Pharmaceuticals
- 05 Jan 2022 Status changed from active, no longer recruiting to completed.
- 30 Aug 2021 Planned End Date changed from 30 Jun 2021 to 30 Dec 2021.
- 30 Aug 2021 Planned primary completion date changed from 31 Mar 2021 to 31 Oct 2021.